These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14563545)

  • 1. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.
    McAleer SD; Mills RJ; Polack T; Hussain T; Rolan PE; Gibbs AD; Mullins FG; Hussein Z
    Drug Alcohol Depend; 2003 Oct; 72(1):75-83. PubMed ID: 14563545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
    Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
    Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
    Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F
    Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
    Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
    J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
    Chiang CN; Hawks RL
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
    Jönsson M; Mundin G; Sumner M
    Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
    Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
    Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
    Gunderson EW; Hjelmström P; Sumner M;
    Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers.
    Fischer A; Jönsson M; Hjelmström P
    Drug Dev Ind Pharm; 2015 Jan; 41(1):79-84. PubMed ID: 24099551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.
    Lim SCB; Schug S; Krishnarajah J
    Pain Med; 2019 Jan; 20(1):143-152. PubMed ID: 29309700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.
    Chawarski MC; Moody DE; Pakes J; O'Connor PG; Schottenfeld RS
    J Subst Abuse Treat; 2005 Dec; 29(4):307-12. PubMed ID: 16311183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
    Haasen C; Linden M; Tiberg F
    J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet.
    Schuh KJ; Johanson CE
    Drug Alcohol Depend; 1999 Aug; 56(1):55-60. PubMed ID: 10462093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.
    Simojoki K; Lillsunde P; Lintzeris N; Alho H
    Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans.
    Schuh KJ; Walsh SL; Stitzer ML
    Psychopharmacology (Berl); 1999 Jul; 145(2):162-74. PubMed ID: 10463317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability.
    van Hoogdalem MW; Tanaka R; Johnson TN; Vinks AA; Mizuno T
    Drug Metab Dispos; 2024 Jul; 52(8):785-796. PubMed ID: 38769016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.
    Bai SA; Xiang Q; Finn A
    Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of buprenorphine/naloxone in opioid-dependent humans.
    Stoller KB; Bigelow GE; Walsh SL; Strain EC
    Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.